- Home
- ELWS vs APLM Comparison
ELWS vs APLM Comparison
Compare ELWS & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- APLM
- Stock Information
- Founded
- ELWS 2018
- APLM 2016
- Country
- ELWS Japan
- APLM United States
- Employees
- ELWS N/A
- APLM N/A
- Industry
- ELWS
- APLM Blank Checks
- Sector
- ELWS
- APLM Finance
- Exchange
- ELWS Nasdaq
- APLM Nasdaq
- Market Cap
- ELWS 6.1M
- APLM 6.9M
- IPO Year
- ELWS 2023
- APLM N/A
- Fundamental
- Price
- ELWS $2.49
- APLM $6.06
- Analyst Decision
- ELWS
- APLM
- Analyst Count
- ELWS 0
- APLM 0
- Target Price
- ELWS N/A
- APLM N/A
- AVG Volume (30 Days)
- ELWS 3.2M
- APLM 28.0K
- Earning Date
- ELWS 07-29-2025
- APLM 08-13-2025
- Dividend Yield
- ELWS N/A
- APLM N/A
- EPS Growth
- ELWS N/A
- APLM N/A
- EPS
- ELWS N/A
- APLM N/A
- Revenue
- ELWS $3,069,669.00
- APLM $198,000.00
- Revenue This Year
- ELWS N/A
- APLM $415.15
- Revenue Next Year
- ELWS N/A
- APLM N/A
- P/E Ratio
- ELWS N/A
- APLM N/A
- Revenue Growth
- ELWS 144.46
- APLM N/A
- 52 Week Low
- ELWS $1.04
- APLM $4.47
- 52 Week High
- ELWS $8.68
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- ELWS 53.96
- APLM 48.70
- Support Level
- ELWS $2.35
- APLM $5.11
- Resistance Level
- ELWS $2.68
- APLM $6.56
- Average True Range (ATR)
- ELWS 0.40
- APLM 0.49
- MACD
- ELWS -0.02
- APLM 0.00
- Stochastic Oscillator
- ELWS 45.74
- APLM 63.42
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.